Tag Archives: BIO Investor Forum

BIO Investor Forum Closing Plenary: How Fragile is the Biotech Rally After Five Positive Years?

2

Last week’s 13th Annual BIO Investor Forum closed on Wednesday with a plenary session asking, “How fragile is the biotech rally after five positive years?” Moderated by Todd Foley, Managing Director, MPM Capital, the panel included: Rachel King, CEO, GlycoMimetics and Chair, BIO Ellen Lubman, VP Strategy and Innovation, Forest Laboratories Vijay Murthy, Director, Ventures and Early Stage Collaborations, AbbVie Michael A. Margolis, RPh, Managing Director, ROTH Capital Partners Doug Fambrough, PhD, CEO, Dicerna Pharmaceuticals Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , ,

A Patient at BIO Investor Forum

BIF-2014

“Sir?” The security guard walks to the Partnering desk, slightly confused. “Sir, there’s a man with no badge. He says he’s not registered for the conference. But he says he needs to talk to you.” At BIO events, you can always expect the unexpected. I nod to the guard. “Let him in.” A man. 70s. Stooped; hunched; gnarled. Disheveled. Faded tattoos on his forearms. Yet, a twinkle in his eye and an unexpected motorcycle helmet Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,

2014 BIO Investor Forum Fireside Chat with Nick Leschly and Chris Collins

bluebird bio

Nick Leschly has served as bluebird bio’s president and chief executive officer since September 2010. Previously, he served as interim chief executive officer from March 2010 to September 2010. Formerly a partner of Third Rock Ventures, L.P. since its founding in 2007, Mr. Leschly played an integral role in the overall formation, development and business strategy of several of Third Rock’s portfolio companies, including Agios Pharmaceuticals, Inc. and Edimer Pharmaceuticals, Inc. Prior to joining Third Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,

Blurred Lines: Investors Explain Their Re-Thinking of Traditional Private-Only or Public-Only Investment Strategies

DSC_8551

The recent expansion and acceleration of the biotech stock market has seen a new willingness and in some cases eagerness to pursue crossover investing in firms pre- and post-IPO. Venture capitalists have become less dogmatic about funding stage and equity share when positive returns seem nearly guaranteed and investment banks are engaging in discussions with entrepreneurs earlier than ever. Relatedly, corporate venture capital executives’ missions have broadened to consider more diverse forms of collaboration than Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,

Gene Therapies Discussed at 2014 BIO Investor Forum

BIO Investor Forum

Since the great excitements and disappointments of gene therapy’s first clinical era, the 1990s, researchers have revised traditional approaches and developed innovative new techniques, including CRISPR/cas-9, to edit genes with greater speed and precision than ever before.  Across a wide range of diseases, gene therapy is showing traction with fresh clinical results and attracting more than $600 million in venture capital in the past two years.  However, real challenges remain in delivery of therapies in Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , ,